An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer.
about
Trial Watch: Adoptive cell transfer for oncological indicationsClassification of current anticancer immunotherapiesPotential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells.Trial Watch: Adoptive cell transfer for anticancer immunotherapy.
P2860
An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
An allogeneic NK cell line eng ...... immunotherapy against cancer.
@en
An allogeneic NK cell line eng ...... immunotherapy against cancer.
@nl
type
label
An allogeneic NK cell line eng ...... immunotherapy against cancer.
@en
An allogeneic NK cell line eng ...... immunotherapy against cancer.
@nl
prefLabel
An allogeneic NK cell line eng ...... immunotherapy against cancer.
@en
An allogeneic NK cell line eng ...... immunotherapy against cancer.
@nl
P2093
P2860
P356
P1433
P1476
An allogeneic NK cell line eng ...... immunotherapy against cancer.
@en
P2093
Cécile Badoual
Hélène Roussel
Marion Mandavit
P2860
P304
P356
10.4161/ONCI.27156
P577
2013-11-14T00:00:00Z